OncoMatch/Clinical Trials/NCT06707259
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
Is NCT06707259 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies anti-CD19 IL10/IL15 CAR-NK for b-cell non hodgkin lymphoma.
Treatment: anti-CD19 IL10/IL15 CAR-NK — To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
The puncture section of the tumor tissue was positive for CD19 expression
Allowed: CD20 negative
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Must have received: anthracycline
Previous treatment must include...anthracyclines
Cannot have received: gene therapy
Exception: allowed if >3 months prior
Have received gene therapy in the past 3 months
Cannot have received: other drugs that target CD19
Have any other drugs that target CD19
Lab requirements
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Glomerular filtration rate >50 mL/min
Liver function
Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL
Cardiac function
Cardiac ejection fraction (EF) ≥50%
Sufficient organ function reserve: (1) Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value); (2) Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; (3) Serum total bilirubin and alkaline phosphatase ≤1.5× UNL; （4）Glomerular filtration rate>50Ml/min Cardiac ejection fraction (EF) ≥50%; (5) Under natural indoor air environment, basic oxygen saturation>92% .
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify